This study is testing PRX-115, a new intravenous (IV) infusion, to see how well it works and if it's safe for adults with gout. You might also receive methotrexate (MTX), a common medication, or a placebo (inactive substance). The study aims to enroll about 150 participants who are at least 18 years old, weigh between 50 and 150 kg, and whose gout hasn't been controlled by other treatments or who can't take those treatments. The main goal is to see what percentage of participants have their serum uric acid (sUA) levels drop below 6 mg/dL after 6 months of treatment. The current recruitment status is unclear.

Study design

This is a randomized, double-blind, placebo-controlled study, meaning participants are randomly assigned to different treatment groups, and neither you nor your doctors will know which treatment you are receiving. It is a Phase II study, and plans to enroll about 150 participants.

What's involved

Participants will receive PRX-115 or a placebo through intravenous (IV) infusions over 24 weeks, according to different schedules. You may also take oral methotrexate or a placebo weekly.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 6 months of treatment, focusing on serum uric acid levels.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.